UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
______________________________
FORM 8-K
CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): October 5, 2021
______________________________
Acadia Healthcare Company, Inc.
(Exact Name of Registrant as Specified in Its Charter)
|
Delaware
|
|
001-35331
|
|
45-2492228
|
|
(State or Other Jurisdiction of Incorporation)
|
|
(Commission File Number)
|
|
(IRS Employer Identification No.)
|
|
6100 Tower Circle,
Suite 1000
Franklin, Tennessee
(Address of Principal Executive Offices)
|
37067
(Zip Code)
|
(615) 861-6000
(Registrant’s Telephone Number, including Area Code)
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (See General Instruction A.2. below):
☐ Written communications pursuant to Rule 425
under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12
under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class
|
|
Trading Symbol
|
|
Name of each exchange on which registered
|
|
Common Stock, $0.01 par value
|
|
ACHC
|
|
The Nasdaq Global Select Market
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or
Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
|
Emerging growth company ☐
|
| If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with
any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. |
☐
|
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory
Arrangements of Certain Officers.
On October 5, 2021, Acadia Healthcare Company, Inc. (the “Company”) announced that Debbie Osteen,
Chief Executive Officer and Director of the Company, will retire as Chief Executive Officer. It is anticipated that Ms. Osteen’s retirement will be effective on January 31, 2022. Following her retirement as Chief Executive Officer, Ms. Osteen will
continue to serve on the Company’s Board of Directors.
A copy of the news release relating to this disclosure is furnished herewith as Exhibit 99.1.
(d) Exhibits
|
Exhibit No.
|
Description
|
| |
|
|
|
|
| |
|
|
104
|
The cover page from this Current Report on Form 8-K, formatted in Inline XBRL
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be
signed on its behalf by the undersigned hereunto duly authorized.
| |
ACADIA HEALTHCARE COMPANY, INC. |
|
| |
|
|
|
|
Date: October 5, 2021
|
By:
|
/s/ Christopher L. Howard |
| |
Name: |
Christopher L. Howard |
|
| |
Title: |
Executive Vice President and General Counsel |
|
| |
|
|
|